Riik: Ameerika Ühendriigid
keel: inglise
Allikas: NLM (National Library of Medicine)
BENAZEPRIL HYDROCHLORIDE (UNII: N1SN99T69T) (BENAZEPRILAT - UNII:JRM708L703)
Aurobindo Pharma Limited
BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE 10 mg
ORAL
PRESCRIPTION DRUG
Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from
Benazepril Hydrochloride Tablets USP, 10 mg are dark yellow, circular, biconvex, beveled edge film-coated tablets debossed with ‘E’ on one side and ‘15’ on the other side. Bottles of 90 NDC 65862-116-90 Bottles of 100 NDC 65862-116-01 Benazepril Hydrochloride Tablets USP, 20 mg are pink, circular, biconvex, beveled edge film-coated tablets debossed with ‘E’ on one side and ‘16’ on the other side. Bottles of 90 NDC 65862-117-90 Bottles of 100 NDC 65862-117-01 Benazepril Hydrochloride Tablets USP, 40 mg are dark pink, circular, biconvex, beveled edge film-coated tablets debossed with ‘E’ on one side and ‘17’ on the other side. Bottles of 90 NDC 65862-118-90 Bottles of 100 NDC 65862-118-01 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP.
Abbreviated New Drug Application
BENAZEPRIL HYDROCHLORIDE - BENAZEPRIL HYDROCHLORIDE TABLET, FILM COATED AUROBINDO PHARMA LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BENAZEPRIL HYDROCHLORIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR USE BENAZEPRIL HYDROCHLORIDE TABLETS. BENAZEPRIL HYDROCHLORIDE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1991 WARNING- FETAL TOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ WHEN PREGNANCY IS DETECTED, DISCONTINUE BENAZEPRIL AS SOON AS POSSIBLE. (5.1) DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND DEATH TO THE DEVELOPING FETUS. (5.1) INDICATIONS AND USAGE Benazepril hydrochloride tablets are an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1) DOSAGE AND ADMINISTRATION Adult Patients: Initiate with 10 mg once daily (or 5 mg if patients is on diuretic). Titrate to 40 mg daily based on blood pressure response. (2.1) Pediatric patients age 6 years and above with glomerular filtration rate (GFR) > 30 mL/min/1.73 m : Initiate with 0.2 mg/kg once daily. Maximum dose is 0.6 mg/kg once daily. Renal Impairment: Initiate with 5 mg once daily in patients with GFR < 30 mL/min/1.73 m (serum creatinine > 3 mg/dL) (2.2) DOSAGE FORMS AND STRENGTHS Tablets: 10 mg, 20 mg, 40 mg CONTRAINDICATIONS Angioedema or history of hereditary or idiopathic angioedema (4) Hypersensitivity (4) Coadministration with aliskiren in patients with diabetes (4) WARNINGS AND PRECAUTIONS Angioedema: Discontinue benazepril and treat appropriately. (5.2) Monitor renal function periodically. (5.3) Monitor blood pressure after initiation. (5.4) Hyperkalemia: Monitor serum potassium periodically. (5.5) Hepatic toxicity: Monitor for jaundice or signs of liver failure. (5.6) ADVERSE REACTIONS The most commo Lugege kogu dokumenti